Loss of the Y Chromosome in Aging Men: Heart, Cancer, and Immune Decline.
How a Silent Change in Blood Cells Raises Heart Attack Risk by 68% and Drives Tumor Growth and What the Latest Research Reveals About Prevention
The Chromosome Your Doctor Never Mentioned
He was 67 years old, exercised three times a week, and had no known heart problems. Yet when researchers analyzed his blood samples as part of a large epidemiological study at Uppsala University in Sweden, they found something he had no way of knowing: nearly 44% of his blood cells had lost the Y chromosome. Not recently — it had been happening slowly, silently, over the previous decade.
This phenomenon has a precise name: mosaic loss of Y chromosome, abbreviated mLOY. For a long time, the medical community treated it as a harmless side effect of cellular aging — an artifact with no real clinical consequences. The reasoning seemed logical enough: the Y chromosome determines male sex during embryonic development and once that process is complete, its biological role appeared to be over.
Seven studies published between 2014 and 2026 in Nature, Science, Nature Reviews Genetics, and the Journal of the American College of Cardiology have since shown that this assumption was wrong.
Loss of the Y chromosome is not a passive sign of aging. In the blood cells of aging men, this loss activates concrete biological mechanisms that damage the heart, promote tumor growth and alter immune surveillance. The phenomenon is also far more common than previously thought. Epidemiological data tell a clear story:
- 2.5% of men at age 40 already show detectable mLOY in a significant proportion of blood cells
- 43.6% of men at age 70 have detectable mLOY in their blood
- 57% of men at age 93 show mLOY in more than half of examined cells
These numbers do not mean that every man with mLOY will develop the associated diseases. The relationship is statistical, not deterministic. But the association with premature mortality, cardiovascular disease and cancer — documented across hundreds of thousands of patients — is no longer something that can be set aside. Understanding how this loss works and what it says about how biological aging progresses at the cellular level can genuinely change how men approach prevention after age 40.
The Y Chromosome Is More Than Just a Sex Switch
For decades, the Y chromosome carried a limited scientific reputation. The smallest of the 46 human chromosomes, with a relatively low number of protein-coding genes, it was sometimes described as a near-vestigial structure: necessary for sex determination, irrelevant for everything else.
The first data to challenge this view came in 2014, published in Nature Genetics. A Swedish research group at Uppsala University, led by Lars Forsberg and Jan P. Dumanski, analyzed more than 1,000 elderly men followed over time and found a clear correlation: men with mLOY in blood cells had significantly shorter survival and higher cancer risk compared to those without detectable Y chromosome loss. It was the first large-scale demonstration that mLOY was not biologically harmless. [1]
But why does losing the Y chromosome in blood cells have such broad effects, in organs and tissues far removed from the reproductive system? The answer lies in a category of genes that tends to go overlooked: those involved in regulating the immune system.
A review published in Nature Reviews Genetics in January 2025 by Bruhn-Olszewska, Markljung, Rychlicka-Buniowska and colleagues clarified this point more completely than any previous study. The Y chromosome contains genes that influence the behavior of T lymphocytes, macrophages, and other circulating immune cells. When these cells lose the Y chromosome during replication in the bone marrow, they change how they patrol tissues and respond to biological threats. This connects directly to what researchers studying epigenetic aging and DNA methylation have documented separately: the same cellular stress pathways that drive chromosomal instability also accelerate immune dysregulation over time. [2]
Not all blood cells lose the chromosome at once. The process starts in hematopoietic stem cells in the bone marrow. When one of these stem cells loses the Y chromosome during division, all of its daughter cells are born without it. Over years, this translates into billions of circulating white blood cells lacking the Y chromosome — cells that reach every organ in the body, including the heart, brain, and tumor tissue.
Your Heart Pays the Steepest Price
In 2022, a study published in Science documented the link between mLOY and cardiovascular disease with a level of mechanistic detail no previous research had achieved. The team led by Soichi Sano and Kenneth Walsh at Boston University School of Medicine demonstrated, in a bone marrow transplant model in male mice, that blood cells lacking the Y chromosome penetrate cardiac tissue and — through derived macrophages — activate the growth factor TGF-β1. This molecular signal triggers excessive production of cardiac fibroblasts that deposit collagen in the myocardium, causing cardiac fibrosis: a progressive stiffening of the heart muscle that compromises its function. [3]
The experimental data in mice were precise: only 40% of animals with Y-chromosome-deficient bone marrow were still alive after 600 days, compared to 60% of controls. When researchers treated the affected animals with antibodies blocking TGF-β1, cardiac function improved in a measurable way. This identified a potential therapeutic target — a molecular point of intervention.
These experimental findings are confirmed by human data. A prospective study published in 2026 in the Journal of the American College of Cardiology — conducted within the ASPREE trial — followed 5,131 men aged 65 or older for a median of 8.4 years. None of the participants had cardiovascular disease at enrollment. After adjusting for traditional risk factors — smoking, blood pressure, cholesterol, diabetes — the results were: [4]
- +14% increased risk of myocardial infarction for each additional standard deviation of mLOY burden
- +68% higher rate of all major cardiovascular events compared to men with low mLOY
- The association held independent of age, BMI, and standard cardiovascular biomarkers
What makes these numbers significant is not just their size, but what they represent: a biological mechanism that operates in parallel with the risk factors doctors currently measure. A man can have normal cholesterol, controlled blood pressure, and no family history of heart disease — and still carry a hidden cardiovascular burden driven by mLOY in his blood cells.
Cancer, Immunity, and the Body’s Failing Defense
The connection between mLOY and cancer was the first to be established — and remains one of the most studied. The original 2014 Nature Genetics paper by Forsberg and Dumanski reported elevated cancer risk across multiple tumor types in men with mLOY. Subsequent research has refined this picture substantially.
A study led by Loftfield and colleagues, published in Science, examined the role of mLOY in shaping the tumor microenvironment — the cellular ecosystem surrounding a cancer. What they found was that mLOY-bearing macrophages and T cells show reduced capacity to identify and eliminate cancer cells inside tumors. Instead of attacking the tumor, they adopt an immunosuppressive phenotype — acting as shields for growing cancer rather than defenders against it. This mechanism is especially relevant for men already managing elevated risk, including those researching prostate cancer diagnosis and genetic testing advances. [5]
This immune evasion mechanism helps explain why mLOY shows up more frequently in men with aggressive cancers than in men with localized or slower-growing disease. The chromosome loss does not simply occur alongside cancer — it may actively change the conditions inside the tumor in ways that favor its expansion.
A separate line of research has examined the relationship between mLOY and cognitive decline. A study by Dumanski and colleagues found that men with detectable mLOY had higher rates of Alzheimer’s disease and non-vascular dementia compared to those without Y chromosome loss in blood cells. The proposed mechanism involves neuroinflammation mediated by microglia — the brain’s resident immune cells — which share developmental origins with blood monocytes. When monocytes carrying mLOY migrate into the brain, they may alter neuroinflammatory signaling in ways that accelerate neurodegeneration. [6]
The scope of mLOY’s effects across organ systems points to a common mechanism: immune cells that lose the Y chromosome behave differently in every tissue they reach. Heart, brain, tumor — the underlying biology is the same. The circulating immune cell becomes the messenger of a chromosomal loss that was never meant to leave the bone marrow.
What Men Can Actually Do With This Information
There is no approved clinical test specifically for mLOY available in standard medical practice as of 2026. The measurement technique used in research — mosaic chromosomal alteration calling from SNP arrays or whole-genome sequencing — remains a research tool. But several practical implications emerge from the current body of evidence, even before specific diagnostics become widely available.
The 2025 Nature Reviews Genetics review by Bruhn-Olszewska and colleagues identified several factors associated with accelerated mLOY accumulation. Smoking appears at the top of the list — the association between cigarette smoking and higher mLOY burden in blood cells is one of the most consistent findings across multiple studies, and it appears to be dose-dependent. Men who quit smoking show slower rates of clonal expansion of mLOY-bearing cells compared to those who continue. [2]
Beyond smoking, the factors associated with faster mLOY accumulation overlap substantially with the risk factors for cardiovascular and metabolic disease already tracked by medicine: chronic inflammation, insulin resistance, exposure to genotoxic agents, and severe long-term sleep disruption. Research on biological age acceleration and environmental exposures has documented these same pathways converging — the cellular stress that drives metabolic aging also accelerates the selective survival of Y-chromosome-deficient blood cell clones.
For men aged 40 and older, the current evidence supports a more attentive approach to cardiovascular prevention — not because mLOY itself is currently measurable in clinical practice, but because the mechanisms it reflects are already influencing risk. Men with significant cardiovascular risk factors, even without family history, may benefit from earlier and more frequent cardiological monitoring. The 2026 ASPREE data suggest that mLOY burden predicts cardiovascular events independently of the standard markers physicians currently use — which means some of that risk is simply not captured by current screening protocols.
Future directions in the field include mLOY as a potential biomarker for cardiovascular and cancer risk stratification, and TGF-β1 inhibition as a therapeutic avenue for men with high mLOY burden and cardiac fibrosis. Neither is available in clinical practice today, but the mechanistic groundwork has been laid. The science has moved well beyond correlation. [7]
What is clear now is that the Y chromosome, long dismissed as the genome’s expendable passenger, is doing something important in every tissue it reaches — and its absence, when it spreads silently through a man’s blood over years, leaves a trace that the body’s organs register long before any symptoms appear.
Scientific References
© 2026 Alice & Marcus Guimarães. All rights reserved.This site is proudly created with WordPress.